entertainment -WSS

entertainment

author：entertainment 2025-08-03 10:40:44 - browse：6694

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Dog Aging Project founders on what lies ahead after losing funding

hotspot

WSS

Flu vaccine reformulation won't be easy, manufacturers warn

Inaction leaves children at risk from dangerous chemotherapy drug

Mass General, Mayo Clinic look to monetize custom

Future doctors need a strong humanities education

Bacterial infection may be ‘key event’ in endometriosis, study says

Listen: Biogen's messy board & Laronde's data problem

hotspot

entertainment

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Meta looks to target Twitter with a rival app called Threads

What does generative AI mean for health care? We asked experts

FDA sets aggressive timeline for overhauling inspection procedures

Continuity nursing helped my family in our darkest PICU moments

FDA sets aggressive timeline for overhauling inspection procedures

How one medical school became remarkably diverse

Pumping milk in bathrooms at health conferences is common

Guidelines to prevent youth baseball injuries need more muscle

Van's Gluten Free Original Waffles recalled for possible wheat allergen

explore

Printout prescription drug information shouldn’t go digital

Maisha Meds is a PBM, but don't call it that

PhRMA sues HHS over Medicare drug price negotiation

Prior authorization reform is both possible and imperative

Did the public have the right to know Arthur Ashe had AIDS?

There's an unseen cost to disruptive road

hotspot

knowledge

explore

knowledge